🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523207-29-00
Completed Phase IV

Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial

2025-523207-29-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire Amiens Picardie
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Not possible to specify
Decision date
17/12/2025
Enrollment target
182
Sites
France

Condition studied

colorectal cancer laparoscopic surgery

Investigational medicinal product(s)

SUFENTANIL KALCEKS 5 microgrammes/mLsolution injectable/pour perfusionDEXAMETHASONE KRKA 8 mg/2 mlsolution injectable/pour perfusionACTISKENAN 5 mggéluleKETAMINE G.L. PHARMA 10 mg/mLsolution injectableParacetamol 10 mg/ml Solution for InfusionCELEBREX 100 mg capsulePropofol Kabi 10 mg/ml emulsion for injection or infusionKETOPROFENACUPANsolution injectableROPIVACAINE B.BRAUN 2 mg/mlsolution injectable/pour perfusionKETOPROFENNEFOPAM BIOGARAN 20 mg/2 mLsolution injectableXYLOCARD 20 mg/ml INTRAVEINEUXsolution injectableParecoxib Seacross 40 mg powder for solution for injection

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Postoperative recovery assessed using the QOR-15 scale twenty-four hours after surgery.

Endpoint detail

Assessment of plasma concentrations of lidocaine (toxic threshold >5 µg/mL) and ropivacaine (toxic threshold >2.2 µg/mL), Signs of local anesthetic toxicity sought in the post-anesthesia care unit (PACU) for up to two hours after the end of the procedure: o Cardiological (conduction disorders, atrioventricular conduction disorders, rhythm disorders, especially ventricular: ventricular tachycardia, ventricular fibrillation, or even cardiac arrest in asystole) o Neurological (perioral tingling, headaches, visual or auditory distortions, tremors in the extremities, loss of consciousness, coma, convulsions), Postoperative pain assessed using the numerical rating scale (NRS) at H2 at rest, H24 at rest and during mobilization, H48 at rest and during mobilization, Maximum pain assessed using the NRS during the first 48 hours, Postoperative analgesic consumption during the first 48 hours, Consumption of morphine derivatives expressed in oral morphine equivalent (mg) per operation and 48 hours post-operatively, Occurrence of dysesthesia (peri-scar hyperalgesia, allodynia, numbness) at the surgical site at 48 hours, Neuropathic pain, defined as a DN4 score > 4/10 at 48 hours and 3 months, The time before resumption of transit (resumption of gas and then bowel movements) and food tolerance will be assessed through daily interviews with the physician., Medical and surgical complications will be assessed using the Clavien Dindo score one month after surgery., Possibility of chemotherapy within two months post-op if indicated by the oncology multidisciplinary team meeting, Length of stay from admission to discharge, expressed in days, Patient satisfaction, assessed using the EVANS score upon discharge

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523207-29-00 on CTIS ↗ ← All trials in the EU